3 Hot Penny Stocks to Add to Your Watchlist in Mid-March
When you are looking to invest in penny stocks, it is important to do your research first. Not all penny stocks are created equal, and some are much riskier than others. There are a few things to keep in mind when looking for penny stocks. The first is that penny stocks are not listed on major exchanges.
Second, penny stocks are not as stable as blue chips, so there is greater potential for fraud. Third, penny stocks are often not as well-known as other stocks, so the frequency at which they move is high. Fourth, penny stocks are more volatile than other stocks, meaning they can go up or down in price very quickly. And while this can be a problem, it can also create opportunity for those who utilize a swing trading method.
Finally, penny stocks are cheaper than their blue chip counterparts, so they tend to be a popular option for those with less money to start investing. Regardless, penny stocks do present a lot of opportunities for investors of all types. But, knowing where to look and how to find them is crucial. With that in mind, let’s take a look at three penny stocks to watch right now.
3 Penny Stocks to Watch in Mid-March 2022
- Eos Enterprises Inc. (NASDAQ: EOSE)
- Clovis Oncology Inc. (NASDAQ: CLVS)
- Atossa Therapeutics Inc. (NASDAQ: ATOS)
Eos Energy Enterprises Inc. (NASDAQ: EOSE)
On March 8th, shares of EOSE stock shot up by over 13% at EOD. This was and is a sizable gain for the company and comes after a five day gain of more than 22%. In the previous few months, shares of EOSE stock have been on a bearish trend. One of the reasons for this is that the company is benefitting from the growth of the energy storage industry. And, the energy industry as a whole has continued to see substantial growth in the past month out so.
While EOSE stock is highly volatile, the company does look like it has a lot to offer investors. The most recent news from Eos Energy came on February 23rd. On the 23rd, it announced its plans to expand its manufacturing facility to more than triple its current output.
During the fourth quarter of 2021, the company saw revenue growth of more than 332% sequentially. This is a major gain and one that shows just how fast the company is growing. So, with all of this in mind, do you think that EOSE stock is worth adding to your list of penny stocks to buy?
Clovis Oncology Inc. (NASDAQ: CLVS)
Another penny stock that has been gaining recently is CLVS stock. On March 8th, CLVS stock shot up by over 4.5%. The most recent news from the company came on February 23rd, when the company announced its financial results for the quarter ended on December 31st.
“We have been looking forward to 2022 for a long time, which we anticipate will be the most significant year for clinical data read-outs in the Company’s history.
Despite the ongoing impact of COVID-19 on ovarian cancer diagnoses and treatments, and consequently on Rubraca revenues in 2021, our commitment to Phase 3 trials has potentially set the stage for significant label expansion, and therefore sales growth, in both the US and Europe.”The CEO of Clovis Oncology, Patrick J. Mahaffy
In its fourth quarter report, the company announced net product revenue for its Rubraca product of $36 million. While this is a 5% decrease sequentially, the company did bring in global net product revenue of $148 million in 2021 as a whole. Right now, there is also a major emphasis on biotech penny stocks. Because of this, CLVS stock is seeing heightened popularity in the market. Considering that, will CLVS be on your penny stocks watchlist or not?
Atossa Therapeutics Inc. (NASDAQ: ATOS)
Another biotech penny stock that has been pushing up in the past few weeks is ATOS stock. However, over the last six months, shares of ATOS have shot down by over 65%. This is a disheartening drop and one that reflects both company-specific factors and the stock market as a whole during that time. One of the biggest recent announcements from Atossa came on March 8th. On the 8th, it announced that it was issued a key patent in the U.S. for its Endoxifen product.
“We are very pleased with the scope and breadth of this new key patent. Patents covering the composition of matter of new therapies are critical to protect markets from generic competition. The ‘151 Patent,’ with its estimated expiration in 2038, strengthens our intellectual property estate and should create long-term stockholder value.”The President and CEO of Atossa, Dr. Steven Quay
For some added context, Atossa is a clinical-stage biopharmaceutical company working on the development of new medicines. Its focus is on the field of oncology and infectious diseases with its sites set on both Breast Cancer and Covid-19 right now.
Because of this, the company has seen more attention in the past few months than it has previously. And although it is highly volatile, it is also working on several novel medicines that could be worth keeping an eye on. With that considered, is ATOS stock a buy or not?
Can Penny Stocks Make Gains in 2022?
Penny stocks can be a good investment if you know what you’re doing. There are a lot of penny stocks that are not worth your time, but if you do your research, you can find the best penny stocks to invest in.
The top penny stocks are usually those that are popular as they tend to move frequently. Penny stocks can be a great investment for those who are willing to do their research. By looking at the financials of a company and its potential, you can find ways to make money with small caps.